Press Release
[Interview] Growth in Four Years... Proprietary Health Supplement 'Technological Expertise' Plays a Key Role
2024.09.06 16:41- 작성자 관리자
- 조회 74
MetaCen Therapeutics, a biotech company specializing in developing treatments for metabolic diseases using glycotoxin-reducing technology, was established in 2015. Since then, the company has focused on distributing health functional foods through professional consultations with hospitals, clinics, and pharmacies.CEO Myoung-Gyu Park, who previously served as a research director at LG Chem, EugeneBio, and Mergens, has a background in developing hyaluronic acid and various new drugs. He is recognized as a leading expert on glycotoxins in South Korea.
After discovering that glycotoxins are a key cause of metabolic diseases, Park founded the AGEs Society, which now has around 1,000 pharmacists as members. Through the association, he has shared knowledge about glycotoxins, gradually increasing awareness within the pharmacy community.
The company’s rapid growth within 3.5 years can be attributed to its robust business model centered around health functional foods. MetaCen Therapeutics has established a network of over 350 pharmacies nationwide and currently offers 21 pharmacy-exclusive products. Among the most popular are their probiotics, which target glycotoxin breakdown, and hyaluronic acid products that aid in moisturizing and mucous membrane regeneration.
Park explained, “Our probiotics are not ordinary; they were developed in collaboration with the Korea Food Research Institute to break down glycotoxins. The hyaluronic acid products, which help with moisturizing and mucous membrane regeneration, are also highly popular among pharmacists. All our products are exclusively available in pharmacies and not sold online.”
He added, "With fast customer feedback and high repurchase rates, pharmacists have developed strong trust in our products. We aim to expand our product line to 30 health functional foods by the end of this year, based on our proprietary technology."
Park's ultimate goal is to develop new drugs, and his dedication to this goal is evident, with 30% of the company’s revenue being invested in R&D. The company currently has four new drug pipelines, including treatments for hepatitis, Parkinson's disease, dementia, and atopic dermatitis, and is actively pushing forward in drug development.
To ensure accuracy, clinical trials are being conducted at Seoul National University Hospital, Veterans Hospital, and other institutions. As a result, investors are taking notice of the company's potential for growth.
Park stated, "Many people only had a superficial understanding of glycotoxins. However, glycotoxins lie at the root of many diseases, and addressing them is key to understanding these conditions. We are currently focused on developing four new drugs, and we expect results from these studies by the end of the year. We are also expecting to publish 2-3 research papers."
Looking ahead, Park's vision is for MetaCen Therapeutics to become a global leader in health functional foods and a global pharmaceutical company specializing in metabolic disease treatments. The company is also aiming for a KOSDAQ listing next year through a technology-specialized approach.
Source: [Yaksa Gongron] (https://www.kpanews.co.kr)